Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.12Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -7.27%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical achievements with successful trial outcomes and a strong financial position. However, these positives were offset by a continued net loss and increased expenses. The positive aspects slightly outweigh the negatives, suggesting a cautiously optimistic outlook.Company Guidance
During the Trevi Therapeutics First Quarter 2025 earnings call, CEO Jennifer Good provided detailed guidance on the company's ongoing clinical trials, including updates on the Phase 2a RIVER trial for refractory chronic cough (RCC) and the Phase 2b CORAL trial for idiopathic pulmonary fibrosis (IPF) chronic cough. The RIVER trial demonstrated a statistically significant reduction in 24-hour objective cough frequency with a P value of less than 0.0001 and a 57% placebo-adjusted reduction in cough from baseline. Trevi also completed enrollment in the CORAL trial, which includes approximately 160 patients across 60 sites in 10 countries, with data expected this quarter. Financially, Trevi reported a net loss of $10.4 million for the first quarter of 2025, with R&D expenses at $7.8 million and G&A expenses at $3.7 million. The company holds $103.3 million in cash and investments, providing a financial runway into the fourth quarter of 2026. Additionally, Trevi has received clear guidance from the FDA on a technical matter related to their program, which is crucial for their ongoing development efforts.Successful Phase 2a RIVER Trial
The Phase 2a RIVER trial in RCC patients met its primary endpoint with a statistically significant reduction in 24-hour objective cough frequency, achieving a P value of less than 0.0001 and a 57% placebo-adjusted reduction in cough from baseline.
Completion of Phase 2b CORAL Trial Enrollment
Trevi completed enrollment of the Phase 2b CORAL trial for IPF chronic cough patients, with approximately 160 patients enrolled across 10 countries and 60 sites.
Strong Financial Position
Trevi reported cash and investments totaling $103.3 million as of March 31, 2025, providing runway into the fourth quarter of 2026.
Positive FDA Interaction
The FDA provided clear guidance on a technical matter through a Type C request, indicating a positive and timely response from the regulatory body.
TRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $6.60 | $6.60 | 0.00% |
Mar 18, 2025 | $6.56 | $6.81 | +3.81% |
Nov 06, 2024 | $3.10 | $2.90 | -6.45% |
Aug 08, 2024 | $2.80 | $2.86 | +2.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Trevi Therapeutics Inc (TRVI) report earnings?
Trevi Therapeutics Inc (TRVI) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Trevi Therapeutics Inc (TRVI) earnings time?
Trevi Therapeutics Inc (TRVI) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TRVI EPS forecast?
TRVI EPS forecast for the fiscal quarter 2025 (Q2) is -0.11.